Craft

Aeglea

Stock Price

$27.7

2024-01-29

Market Capitalization

$48.6 M

2024-01-29

Revenue

$886 K

FY, 2023

Aeglea Summary

Company Summary

Overview
Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics. It specializes in the field of amino acid metabolism to treat rare genetic diseases and cancer.
Type
Public
Status
Active
Founded
2013
HQ
Austin, TX, US | view all locations
Website
https://www.aeglea.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jonathan D. Alspaugh

    Jonathan D. Alspaugh, Chief Financial Officer

  • Cortney Caudill

    Cortney Caudill, Chief Product Officer

  • Joseph E. Tyler

    Joseph E. Tyler, Vice President of Manufacturing

  • Linda Neuman

    Linda Neuman, Chief Medical Officer

LocationsView all

1 location detected

  • Austin, TX HQ

    United States

    805 Las Cimas Pkwy #100

Aeglea Financials

Summary Financials

Net income (Q1, 2025)
($44.8M)
Cash (Q1, 2025)
$48.5M
EBIT (Q1, 2025)
($53.6M)

Footer menu